DataMEDS SI Cuts Costs to Focus on Tumor Diagnostic Test Expansion

Pittsburgh, Tuesday, 13 October 2026.
DataMEDS SI restructured operations on October 13, 2026, pivoting to commercialize its ChemoFx cancer assay, a test backed by a repository of over 70,000 tumor samples.